Company Encyclopedia
View More
name
abrdn Healthcare Opportunities
THQ.US
News
View More

Why the Stock Price of This Cancer Screening Company Soared 17% Thursday

Abbott Laboratories has agreed to acquire Exact Sciences Corp. for $21 billion, paying shareholders $105 per share. Exact Sciences, known for its cancer screening tests like Cologuard, expects to generate about $3 billion in revenue this year. This acquisition is part of a broader trend of pharmaceutical companies investing heavily in cancer screening development.

MSN·
US
EXAS
+16.81%
US
ABT
-1.73%
MSN·
US
EXAS
+16.81%
US
ABT
-1.73%

With UnitedHealth Stock (UNH) Down Over 38%, Let's Look at Who Owns It

UnitedHealth Group (UNH) stock has dropped over 38% this year due to high medical costs and a DOJ investigation. Despite this, the company reported strong Q3 results and raised its earnings outlook. Analysts remain optimistic about its growth. Berkshire Hathaway's purchase of over 5 million shares shows confidence in UNH. Currently, public companies and individual investors own 49.17% of UNH, followed by mutual funds, ETFs, other institutional investors, and insiders.

Tip Ranks·
US
UNH
+0.79%
Tip Ranks·
US
UNH
+0.79%

Health Care Down, But not by Much, Amid Deal Activity -- Health Care Roundup

Health-care companies fell slightly amid deal activity. Exact Sciences surged after Abbott Laboratories agreed to acquire it for $21 billion. Moderna aims to stop losing money by 2028, despite taking a $1.5 billion loan. A CDC webpage now suggests vaccines might cause autism, reflecting changes under Health and Human Services Secretary Robert F. Kennedy.

marketscreener·
US
ABT
-1.73%
US
EXAS
+16.81%
US
MRNA
-7.53%
marketscreener·
US
ABT
-1.73%
US
EXAS
+16.81%
US
MRNA
-7.53%

TherapeuticsMD Inc. Stock Outperforms Competitors On Strong Trading Day

TherapeuticsMD Inc. (TXMD) stock surged 16.36% to $1.92 on Thursday, outperforming competitors despite a poor trading session for the market. The NASDAQ fell 2.15% and the Dow Jones dropped 0.84%. This marks the third consecutive day of gains for TXMD, which closed 21.31% below its 52-week high. Trading volume exceeded its 50-day average. AbbVie Inc. (ABBV) fell 1.49%.

Dow Jones·
US
TXMD
+16.36%
US
ABBV
-1.49%
Dow Jones·
US
TXMD
+16.36%
US
ABBV
-1.49%

AbbVie Inc. Stock Underperforms Thursday When Compared To Competitors

AbbVie Inc.'s stock fell 1.49% to $229.45 on Thursday, marking its third consecutive day of losses. The stock closed 6.27% below its 52-week high. In comparison, Johnson & Johnson rose 0.28%, while Pfizer and Amgen fell 1.93% and 1.85%, respectively. Trading volume was 1.9 million below the 50-day average. The S&P 500 and Dow Jones also experienced declines.

Dow Jones·
US
ABBV
-1.49%
Dow Jones·
US
ABBV
-1.49%